HOMOLOGY MEDICINES INC (FIXX) Stock Analyst Ratings
USA - NASDAQ:FIXX - US4380831077 - Common Stock
0.9347 USD
+0.01 (+0.77%)
0.892 USD
-0.04 (-4.57%)
ChartMill assigns a Buy % Consensus number of 43% to FIXX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 1.53. This target is 63.69% above the current price.
FIXX was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about FIXX.
In the previous month the buy percentage consensus was at a similar level.
FIXX was analyzed by 6 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-07-28 | Baird | Downgrade | Outperform -> Neutral |
| 2023-05-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-12 | Chardan Capital | Maintains | Buy -> Buy |
| 2023-05-12 | Credit Suisse | Reiterate | Neutral -> Neutral |
| 2023-03-16 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-11-17 | Chardan Capital | Maintains | Buy |
| 2022-11-11 | RBC Capital | Maintains | Sector Perform |
| 2022-08-31 | Baird | Maintains | Outperform |
| 2022-08-16 | Chardan Capital | Maintains | Buy |
| 2022-08-16 | BTIG | Maintains | Buy |
| 2022-08-16 | Credit Suisse | Maintains | Neutral |
| 2022-05-17 | Credit Suisse | Maintains | Neutral |
| 2022-04-28 | Credit Suisse | Initiate | Neutral |
| 2022-02-28 | HC Wainwright & Co. | Maintains | Buy |
| 2022-02-22 | Chardan Capital | Maintains | Buy |
| 2022-02-22 | BTIG | Maintains | Buy |
| 2022-02-22 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2022-02-22 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2022-02-22 | B of A Securities | Maintains | Buy |
| 2021-11-16 | Chardan Capital | Maintains | Buy |
| 2021-03-02 | Stifel | Initiate | Hold |
HOMOLOGY MEDICINES INC / FIXX FAQ
What is the price target for FIXX stock?
6 analysts have analysed FIXX and the average price target is 1.53 USD. This implies a price increase of 63.69% is expected in the next year compared to the current price of 0.9347.
Can you provide the consensus rating for HOMOLOGY MEDICINES INC stock?
The consensus rating for HOMOLOGY MEDICINES INC (FIXX) is 43.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
How many analysts cover HOMOLOGY MEDICINES INC (FIXX) stock?
The number of analysts covering HOMOLOGY MEDICINES INC (FIXX) is 6.